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For the Love of Drugs: Using Pharmaceutical 
Clinical Trials Abroad to Profit Off the Poor 
     Breanne M. Schuster* 
INTRODUCTION 
“No, there are no murders in Africa. Only regrettable deaths. And from 
those deaths we derive the benefits of civilization, benefits we can afford so 
easily . . . because those lives were bought so cheaply.”1 
The global pharmaceutical market is worth $300 billion a year, a figure 
that is expected to increase to $400 billion within the next three years.2 In 
2012 alone, the 11 largest global pharmaceutical companies raked in nearly 
$85 billion in net profits,3 and drug companies’ CEOs drew virtually $200 
million in total compensation.4 Profits, however, require sacrifices. While 
                                                                                                                  
* Breanne Schuster is a recent graduate of Seattle University School of Law and a former 
Executive Editor of the Seattle Journal for Social Justice. She would like to thank the 
journal for choosing her article for publication as well as the editors who dedicated their 
time and expertise to this piece. Breanne would also like to thank all of the amazing 
people in her life who have continually kept her sane, motivated, and smiling. 
1 THE CONSTANT GARDENER (Focus Features 2005) (based off the novel of the same 
title by John le Carre). It is alleged that le Carre drew his inspiration for the book from 
the Trovan pharmaceutical scandal. See generally Jim Edwards, Claim: LeCarre’s “The 
Constant Gardener” Was Based on Pfizer Trovan Case, CBS MONEYWATCH (Feb. 17, 
2009, 9:39 PM), http://www.cbsnews.com/8301-505123_162-42840653/claim-lecarres-
the-constant-gardener-was-based-on-pfizer-trovan-case/. 
2 Pharmaceutical Industry, Trade, Foreign Policy, Diplomacy and Health, WORLD 
HEALTH ORG., http://www.who.int/trade/glossary/story073/en/ (last visited Feb. 18, 
2015) [hereinafter WHO]. 
3 Thom Hartmann, 11 Major Drug Companies Raked in $85 Billion Last Year, and Left 
Many to Die Who Couldn’t Buy Their Pricey Drugs, ALTERNET (Apr. 30, 2013), 
http://www.alternet.org/11-major-drug-companies-raked-85-.billion-last-year-and-left-
many-die-who-couldnt-buy-their-pricey. 
4 Ethan Rome, Big Pharma CEOs Rake in $1.57 Billion in Pay, HUFFINGTON POST 
(May 8, 2013 8:19 AM), http://www.huffingtonpost.com/ethan-rome/big-pharma-ceo-
pay_b_3236641.html. 
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pharmaceutical companies have seen a near 50 percent increase in profits 
since 2005,5 India has watched almost 3,000 of its citizens lose their lives to 
support these industry gains.6 India is just one of the emerging hot spots for 
clinical trials; much of the developing world is vulnerable to pharmaceutical 
invasion.7 The more unfamiliar and remote the city might appear to the 
average layperson, the more attractive it seems to be to a company or 
institution. Desperate populations are prime candidates for clinical trials, 
and it is clear that the sponsors8 of these trials are able to get away with 
virtually anything. In India, only 82 people out of 2,868 have been 
compensated thus far for deaths occurring during recent clinical trials.9  
  Since 1990, drug trials conducted in foreign countries have increased 
over 2,000 percent.10 In 2010, Inspector General of the Department of 
Health and Human Services Daniel Levinson issued a report titled 
Challenges to FDA’s Ability to Monitor and Inspect Foreign Clinical 
Trials, which found that at least 80 percent of drugs approved for sale in the 
United States were based off trials conducted either primarily or entirely in 
                                                                                                                  
5 Diane Archer, Strengthen Medicare: End Drug Company Price Setting, HEALTH 
AFFAIRS BLOG (May 28, 2013), http://healthaffairs.org/blog/2013/05/28/strengthen-
medicare-end-drug-company-price-setting/. 
6 Ranjita Biswas, Over 2,500 Deaths During Indian Clinical Trials, INTER PRESS SERV. 
NEWS AGENCY (Nov. 5 2013), http://www.ipsnews.net/2013/11/over-2500-deaths-
during-indian-clinical-trials/. 
7 See, e.g., Michael Carome, Unethical Clinical Trials Still Being Conducted in 
Developing Countries, HUFFINGTON POST (Dec. 3, 2014), http://www.huffingtonpost. 
com/michael-carome-md/unethical-clinical-trials_b_5927660.html. 
8 21 C.F.R. § 50.3(d)–(e) (2000) (defining a sponsor as the person who initiates a 
clinical trial, as opposed to an investigator, who actually conducts the clinical trial). 
9 S. Srinivasan, When Clinical Trials Become Dangerous, THE HINDU BUS. LINE (Oct. 
15, 2013), http://www.thehindubusinessline.com/opinion/when-clinical-trials-become-
dangerous/article5237461.ece. 
10 Donald L. Barlett & James B. Steele, Deadly Medicine, VANITY FAIR (Jan. 2011), 
available at http://www.vanityfair.com/politics/features/2011/01/deadly-medicine-201 
101. 
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a foreign country.11 While Federal Drug Administration (FDA)-regulated 
trials abroad have consistently increased every year in the past decade, 
clinical trials in the United States have seen a 5.5 percent annual decline.12 
This significant increase—and disparity—is troublesome because history 
has demonstrated the frequently unethical nature of clinical trials conducted 
abroad by US companies and institutions.13 A number of failed clinical 
trials have made it clear that the potential profit benefits of these trials 
receive greater weight than human rights and ethical considerations. 
For example, in the early 1990s, there were predictions that 
Trovafloxacin Mesylate (commonly known as Trovan), an antibiotic 
sponsored by the pharmaceutical company Pfizer, could be one of the most 
financially successful new drugs of its kind, with an estimated $1 billion a 
year in profits.14 Animal testing suggested that the drug “had life-
threatening side effects including joint disease, abnormal cartilage growth, 
liver damage, and a degenerative bone condition.”15 However, in 1996, a 
meningitis outbreak in Nigeria presented the perfect opportunity to test 
these feared effects.16 Some doctors warned against the experiments, but 
                                                                                                                  
11 DANIEL R. LEVINSON, DEP’T OF HEALTH AND HUMAN SERV., CHALLENGES TO 
FDA’S ABILITY TO MONITOR AND INSPECT FOREIGN CLINICAL TRIALS 10 (June 2010), 
http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf. 
12 Id. at 20. 
13 E.g., Carome, supra note 7; SOMO Briefing Paper on Ethics in Clinical Trials, #1: 
Examples of Unethical Trials, SOMO & WEMOS, (Feb. 2008), available at http://www. 
wemos.nl/files/Documenten%20Informatief/Bestanden%20voor%20’Medicijnen’/examp
les_of_unethical_trials_feb_2008.pdf. 
14 Sonia Shah, Globalizing Clinical Research, THE NATION 3 (Jul. 1, 2002), http://www. 
thenation.com/article/globalizing-clinical-research#; Joe Stephens, Where Profits and 
Lives Hang in Balance, WASH. POST 1 (Dec. 17, 2000), http://www.washingtonpost.com/ 
wp-dyn/content/story/2008/10/01/ST2008100101390.html. 
15 Abdullahi v. Pfizer, Inc., 562 F.3d 163, 169 (2d. Cir. 2009). 
16 Stephens, supra note 14. 
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those who spoke up were dismissed shortly after.17 An infectious-disease 
specialist for the company who cautioned executives that the study was “a 
violation not only of medical ethics but of federal and international laws” 
was also subsequently fired.18 
Clinical testing was approved within one day for Kano, Nigeria, and, 
while Pfizer initially claimed it had secured approval from an ethics 
committee, evidence suggested that the approval letter was backdated well 
after the experiments had taken place and that there was no ethics 
committee in place at the time of “approval.”19 Pfizer eventually conducted 
its own investigation, which also proved that the certificate was 
“incorrect.”20 
Prior to the trial, Doctors Without Borders set up a camp nearby to treat 
patients with known successful (and free) treatment. Subjects21 in Pfizer’s  
trials of Trovan were not informed of this alternative, nor were they 
informed of the experimental nature of the study or the risks involved.22 
Participants were not asked for their consent in English or the subjects’ 
                                                                                                                  
17 Tamar Lewin, Families Sue Pfizer on Test of Antibiotic, N.Y. TIMES (Aug. 30, 2001), 
http://www.nytimes.com/2001/08/30/business/families-sue-pfizer-on-test-of-
antibiotic.html. 
18 Walter Armstrong, Did Pfizer Bribe Its Way Out of Criminal Charges in Nigeria?, THE 
ATLANTIC (Dec. 27, 2010), http://www.theatlantic.com/international/archive/2010/12/did 
-pfizer-bribe-its-way-out-of-criminal-charges-in-nigeria/68495/. 
19 Abdullahi, 562 F.3d at 170. 
20 Donald McNeil, Nigerians Receive First Payments for Children who Died in 1996 
Meningitis Drug Trial, N.Y. TIMES (Aug. 11, 2011), http://www.nytimes.com/2011/ 
08/12/world/africa/12nigeria.html?_r=0. 
21 The choice of the word “subjects” is a conscious one. Unlike “participants,” who play 
an active and consensual role in an activity, “subjects” are individuals under the control 
and authority of a particular body. Furthermore, dissimilar to participants who might 
expect some sort of benefit for their participation, subjects connotes an ability to use and 
subsequently abandon the humans, as if they were mice in a science experiment. 
22 Armstrong, supra note 18.  
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native language of Hausa, and no consent forms were filed.23 Once the trial 
began, proper protocols per US guidelines continued to be abandoned. For 
example, blood was not tested upon arrival and subjects showing no 
improvement were not removed from the trial and given proper treatment, 
despite the fact that these are common procedures for similar trials 
conducted in the United States.24 Additionally, many children received an 
oral form of the medication even though an IV25 was the normal and only 
previously tested protocol, and many were given injections in improper 
places. Some children in the study received only as much as one-third of the 
recommended dosage of the control drug ceftriaxone, many allege, in order 
to boost the apparent success of the trial.26 There were no specialists or 
requisite equipment to look for damage to the subjects during and after the 
studies.27 And, the sponsor itself admitted that 20 percent of subjects 
received treatment that deviated from the pre-approved plan of care.28 
After two weeks, Pfizer left Kano, without leaving records for the 
majority of its 200 test subjects.29 The sponsor did, however, leave behind 
11 dead children, and many others with brain damage, paralysis, deafness, 
and slurred speech.30 After the trials were completed, dozens of 
discrepancies in test results were discovered.31 
                                                                                                                  
23 David Smith, Pfizer Pays out to Nigerian Families of Meningitis Drug Trial Victims, 
THE GUARDIAN (Aug. 11, 2011), http://www.theguardian.com/world/2011/aug/11/pfizer-
nigeria-meningitis-drug-compensation. 
24 Stephens, supra note 14, at 5. 
25 An IV (intravenous) is “a device that is used to allow a fluid (such as blood or a liquid 
medication) to flow directly into a patient’s veins[.]” MERRIAM-WEBSTER, http://www. 
merriam-webster.com/dictionary/iv (last visited Apr. 10, 2015). 
26 Stephens, supra note 14, at 5. 
27 Id. 
28  Id. 
29 Id. 
30 Smith, supra note 23. 
31 Stephens, supra note 14, at 5. 
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Still, the drug was approved for market in the United States. Even though 
testing was done solely on children, Trovan was ultimately approved only 
for people 14 years old and older because of its potential side effects.32 
Europe suspended sales altogether due to its concern about liver toxicity, 
but the United States found the drug more marketable.33 That is, until there 
were so many reports of liver damage and deaths that the FDA had to take 
the drug off the market. Pfizer raked in millions of dollars before being 
sued.34 
Because the company failed to track long-term recovery of its patients, 
the only reason the scandal was uncovered was because of an investigation 
completed by the Washington Post.35 Plaintiffs settled with Pfizer out of 
court, but only after Pfizer allegedly hired investigators to look into 
evidence of corruption against the Nigerian attorney general in order to 
dissuade real legal consequences for its actions.36 The majority of harmed 
subjects and their families have yet to obtain any actual compensation.37 
The worst part about all of this, however, is that the Trovan scandal is far 
from unordinary. As Charles Medawar, director of Social Audit, a UK 
group that monitors the pharmaceutical industry, stated, “This particular 
case looks to be very bad, but I hardly think it is untypical.”38 
                                                                                                                  
32 Id. 
33 Smith, supra note 23. 
34 See Shah, supra note 14; Abdullahi v. Pfizer, Inc., 562 F.3d 163, 163 (2d. Cir. 2009). 
35 The Washington Post subsequently published a series of articles regarding the Trovan 
experiments and clinical trials abroad generally. Stephens, supra note 14; Mary Pat 
Flaherty et al., Testing Tidal Wave Hits Overseas, WASH. POST, Dec. 18, 2000, at 4, http: 
//www.washingtonpost.com/wp-dyn/content/article/2008/10/01/AR2008100101117.html; 
Sharon LaFraniere et al., The Dilemma: Submit or Suffer ‘Uninformed Consent’ Is Rising 
Ethic of the Drug Test Boom, WASH. POST, Dec. 19, 2000, http://www.washington 
post.com/wp-dyn/content/article/2008/10/01/AR2008100101150.html?sid=ST200810010 
1390. 
36 Smith, supra note 23. 
37 Id. 
38 Jacqui Wise, Pfizer Accused of Testing New Drug Without Ethical Approval, BRIT. 
MED. J. (Jan. 27, 2001), http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1119465/. 
For the Love of Drugs 1021 
VOLUME 13 • ISSUE 3 • 2015 
Despite the significant increase in clinical trials conducted in foreign 
countries, regulations have remained fairly flexible and consistent with past 
inadequate standards. Congress and other regulatory agencies, including the 
FDA, still decline to hold individuals’ conduct abroad to the same standards 
as if they were in the United States. The impact on citizens worldwide has 
been, and will continue to be, devastating. Thus, US pharmaceutical 
companies need to be held accountable for trials they conduct abroad. 
Part I of this paper will discuss the increase in clinical trials conducted 
abroad, their potential benefits, and how pharmaceutical companies defend 
their actions. Part II will discuss why clinical trials conducted in other 
countries are particularly dangerous and subject to unethical behavior. Part 
III will discuss how a clinical trial actually works, and the current system of 
regulation, oversight, and enforcement in place in the United States 
compared to foreign countries. Part IV will examine the inadequacy of 
existing regulations and challenges to oversight and enforcement of trials 
conducted abroad, as well as why potential avenues for relief currently fall 
short. 
Lastly, in Part V, I will offer a number of proposals to ensure 
pharmaceutical accountability. First, at a minimum, all drug trials 
conducted abroad should be held to the same requirements as those in the 
United States. Second, the FDA should require mandatory reporting to a 
public registry with standardized data, and the FDA should continue to 
develop more efficient methods of clinical trial risk assessment. Third, more 
inspections in foreign countries should be conducted, and the FDA should 
work more closely with foreign bodies to ensure the safety of subjects 
enrolled in clinical trials overseas. Fourth, the funding of clinical trials 
should be at the expense of the sponsor conducting the trial. Fifth, 
populations abroad should be automatically considered “vulnerable” and 
afforded the same additional protections populations defined as vulnerable 
in the United States receive. Finally, the FDA should use its authority to 
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enforce violations of clinical trial standards, and governments worldwide 
should look to other potential remedies as well to ensure compliance. 
I. WHY PHARMACEUTICAL COMPANIES CONDUCT TRIALS ABROAD 
Conducting trials abroad has gained popularity for a number of reasons. 
First, it saves pharmaceutical companies time, money, and resources. 
Second, while the legitimacy of this argument is debatable, companies 
articulate that clinical trials conducted in foreign countries benefit global 
health. As such, pharmaceutical companies have a number of concerns 
about the increased regulation of these trials. 
A. Potential Benefits: Time, Money, and Resource Savings 
It should not be much of a surprise that an industry driven by profits 
outsources; conducting clinical trials outside of the United States is much 
cheaper and may allow for a speedier generation of profits.39 A 
pharmaceutical drug trial costs approximately $180 million in the United 
States.40 In other countries, particularly unindustrialized nations, companies 
often pay less than half as much.41 One reason for this disparity is that the 
salaries of physicians, nurses, and study coordinators in other countries are 
lower.42 In India, for example, a first-rate academic center charges 
approximately $1,500 to $2,000 per case report; this is one-tenth of the cost 
at a second-tier center in the United States.43 In addition, time can cost 
                                                                                                                  
39 See Tim Sandler, In India, Oversight Lacking in Outsourced Drug Trials, NBC NEWS 




42 See generally Seth W. Glickman et al., Ethical and Scientific Implications of the 
Globalization of Clinical Research, 360 NEW ENG. J. MED. 816 (2009), http://www.nejm. 
org/doi/full/10.1056/NEJMsb0803929. 
43 Id. 
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millions.44 In the year 2000, it cost approximately $802 million to produce a 
new drug. Time accounted for approximately half of that cost.45 Trials can 
be completed more quickly outside of the United States. Not only is the 
time for drug approval generally shorter, but conducting trials abroad may 
also allow companies to examine seasonal diseases without waiting for the 
disease to be “in season” in the United States.46 
It is also easier to find patients, and to find the “right” patients outside of 
the United States, particularly in developing nations. In the United States, 
approximately one out of 350 people are willing to do drug testing,47 and 
one-third of research and development time is spent on patient 
recruitment.48 Relatedly, one report found that the average number of 
subjects at foreign sites was 505, but domestic sites had a mere 75 
subjects.49 One reason for this phenomenon is that, in many developing 
countries, patients are without other alternatives to meet their basic needs. 
2.6 billion citizens in the world live on less than two dollars a day and they 
live primarily in developing nations.50 In some countries, as many as 85 
percent of constituents live below the international poverty line.51 
Participating in a clinical trial might be the only method by which a patient 
                                                                                                                  
44 Id. 
45 Id. at 817. 
46 Charles W. Schmidt, Monitoring Research Overseas, 4 MED. DRUG DISCOVERY 25, 
25–26 (2001), available at http://pubs.acs.org/subscribe/archive/mdd/v04/i02/html/rules. 
html. Some diseases, like malaria, are particularly prevalent during certain seasons of the 
year or in specific climates. By outsourcing trials to countries with different seasons or 
climates, US companies do not have to wait for the disease to develop at home. Id. 
47 Shah, supra note 14, at 1. 
48 See S. Anoop Pillai et al., Malady of Clinical Trials in India, 44 PHARMA TIMES 12, 
19 (2012), available at https://www.yumpu.com/en/document/view/23478059/malady-
of-clinical-trials-in-india-indian-pharmaceutical-association. 
49 LEVINSON, supra note 11, at 11. 
50 See World’s Poorest Countries, INFOPLEASE, http://www.infoplease.com/ipa/A09087 
63.html (last visited Feb. 19, 2015) (summarizing Human Development Reports). 
51 See Poverty and Equity Data, THE WORLD BANK, http://data.worldbank.org/topic/ 
poverty (last visited Feb. 21, 2014). 
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can pay for food, and, if the patient is ill, it might be the only way they can 
access any form of medical care. Additionally, doctors are more likely in 
other countries to mention or recommend trials to patients, either because 
they may personally receive financial incentives for their encouragement, or 
they recognize that their patients lack any other options.52 In many 
unindustrialized countries, more than half of citizens cannot access “even 
the most basic drugs.”53 As such, it is also easier to find drug-naïve 
participants in other countries (which is often ideal for pharmaceutical 
companies) compared to the United States, where citizens spend an average 
of $898 on their medication—123 percent more than citizens in developing 
nations make a year.54 
Time, money, and resources are also saved because of more lax standards 
in other countries. Clinical trials in the United States severely strain 
research budgets and generally strip federal funding.55 US regulations have 
recently grown in complexity, increasing the burden on investigators in 
terms of compliance, documentation, and training.56 Abroad, there are far 
fewer regulations and obstacles to bypass when conducting trials. Money is 
also saved by less competitive markets. The United States, European 
Economic Community, and Japan account for 90 percent of the world’s 
pharmaceutical research.57 Thus, when US companies conduct research in 
                                                                                                                  
52 Dennis M. Coyne, International Pharmaceutical Mistrials: Existing Law for the 
Protection of Foreign Human Subjects and a Proposal for Reform, 29 B.U. INT’L L.J. 
427, 429 (2011). 
53 Solomon R. Benatar, Distributive Justice and Clinical Trials in the Third World, 22 
THEORETICAL MED. BIOETHICS 169, 171 (2001). 
54 See Tara Culp-Ressler, Prescription Drug Spending Drops as Struggling Americans 
Are Forced to Cut Back on Health Care, THINKPROGRESS (May 10, 2013, 4:25 PM), 
http://thinkprogress.org/health/2013/05/10/1993841/prescription-drug-spending-drops/. 
55 Glickman et al., supra note 42. 
56 Id. 
57 E.g., Rosemarie Kanusky, Pharmaceutical Harmonization: Standardizing Regulations 
Among the United States, the European Economic Community, and Japan, 16 HOUS. J. 
INT’L L. 665, 667 (1994). 
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South America, Africa, or most of Asia, they are not competing with many 
companies from those countries, which saves them additional time, 
resources, and profits. Further, these trials allow for even greater profits 
should companies be able to expand in the foreign market. Many 
governments want testing done on individuals in their own countries before 
they will allow a drug to be marketed.58 
History has shown that there are plenty of profits to gain in the field, and 
the more quickly new drugs are marketed, the faster these profits generate. 
As the number one monetary contributor to lobbying, pharmaceutical 
companies have demonstrated that they will do anything to maintain these 
profits.59 However, changing patent laws and the increasing cost of research 
have the potential to offset some of these profits.60 By looking abroad, 
pharmaceutical companies are sure to maximize their revenue. 
B. Potential Defenses: Pharmaceutical Company Concerns About 
Additional Regulations 
Companies, of course, do not attribute the increase in clinical trials 
abroad to profit goals, and the sheer increase of clinical trials abroad is not a 
problem in and of itself. Pharmaceutical companies have presented multiple 
arguments emphasizing the benefits of these trials. Companies have argued, 
first, that foreign clinical trials are beneficial for global health. They have 
claimed that they allow increased access to healthcare and improve the 
                                                                                                                  
58 Schmidt, supra note 46. 
59 See Top Industries, OPENSECRETS.ORG CTR. FOR RESPONSIVE POL., http://www.open 
secrets.org/lobby/top.php?indexType=i (last visited Mar. 8, 2014). 
60 Blake Wilson, Clinical Studies Conducted Outside of the United States and Their Role 
in the Food and Drug Administration’s Drug Marketing Approval Process, 34 U. PA. J. 
INT’L L. 641, 642 (2013). Patents on pharmaceutical drugs typically last for 20 years, 
usually with few options to extend, after which the drug may be produced by any 
“qualified manufacturer” (i.e., it becomes generic). Id. 
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health of children around the world.61 Drug trials also provide a method for 
patients who would not otherwise be able to access treatment an opportunity 
to receive medical care, including medication they may need.62 Companies 
additionally claim that foreign physicians, investigators, and medical sites, 
including hospitals, can get additional experience working with recent drugs 
and may obtain global recognition for their work.63 Furthermore, trials 
abroad may help to shed valuable light on global diseases and ethnic 
differences that conducting research limited to the United States could not 
provide.64 Clinical trials abroad may also foster global clinical innovation 
and “positive relationships among clinician investigators globally” as well 
as “answer[] questions about the safety and efficacy of drugs and devices 
that are of interest throughout the world.”65 There is a great deal of public 
pressure on pharmaceutical companies and other research institutions to 
develop life-saving drugs. Conducting research abroad may address these 
concerns in a quicker and less costly manner.66 
In light of the alleged benefits of conducting clinical trials abroad, there 
are also numerous concerns about increasing regulation of these trials 
conducted overseas. First, pharmaceutical companies have logistical 
concerns about more stringent standards. They fear that stricter regulations 
would effectively stop other countries from participating in clinical trials.67 
                                                                                                                  
61 Danielle Burstein et al., Questions Abound as Pediatric Clinical Trials Move 
Overseas, DUKE MED. NEWS AND COMM. (Aug. 23, 2010), http://www.dukehealth.org/ 
health_library/news/questions_abound_as_pediatric_clinical_trials_move_overseas. 
62 Anoop Pillai et al., supra note 48. 
63 Id. 
64 Ben Hirschler, Special Report: Big Pharma’s Global Guinea Pigs, REUTERS (May 6, 
2011, 11:14 AM), http://www.reuters.com/article/2011/05/06/us-pharmaceuticals-trials-
idUSTRE7450SV20110506. 
65 Glickman et al., supra note 42. 
66 Burstein et al., supra note 61.  
67 Natalie Blazer, Regulation of Overseas Clinical Trials: FDS vs. Industry, PROD. LIAB. 
MONITOR (May 31, 2013), http://product-liability.weil.com/pharmaceutical-
law/regulation-of-overseas-clinical-trials-fda-vs-industry/. 
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Companies also claim that they would be unable to get proper 
documentation from foreign entities to comply with more rigid rules.68 
Additionally, they argue that the economic incentives (approval of the drug 
for marketing) are enough on their own to ensure the trials are carried out 
properly.69 Lastly, pharmaceutical companies assure activists that additional 
regulations are unnecessary: that all countries basically have the same 
standards anyway.70 
Companies also have some legitimate cultural and ethical claims. Some 
argue that not allowing these trials is paternalistic. Who are we to tell 
populations they should not and cannot access experimental treatments?71 
Cultural and ethical imperialism concerns are not limited to those with a 
stake in the profits.72 There are fears from multiple organizations that 
changing regulations to match those of the United States will disrespect the 
integrity of the community where research is conducted. Additionally, there 
is concern that some physicians in host countries are opposed to universal 
requirements. Foreign researchers and physicians might instead prefer that 
local health experts, bioethicists, and affected groups have the opportunity 
to assess the risks and benefits of each trial.73 Relatedly, arguably, changing 
requirements still does not change the underlying radical power disparity 
between researchers conducting the clinical trials and the subjects 
participating in them. There are frequently significant gaps in knowledge, 
authority, and wealth—is there any way to equalize a relationship where 
                                                                                                                  
68 Id. 
69 Kevin B. O’Reilly, Outsourcing Clinical Trials: Is It Ethical to Take Drug Studies 
Abroad?, AM. MED. NEWS (Sept. 7, 2009), http://www.amednews.com/article/20090907/ 
profession/309079969/4/. 
70 Schmidt, supra note 46. 
71 O’Reilly, supra note 69. 
72 Makau Wu Mutua, The Ideology of Human Rights, 36 VA. J. INT’L L. 589, 592 (1996). 
73 Benjamin Mason Meier, International Protection of Persons Undergoing Medical 
Experimentation: Protecting the Right of Informed Consent, 20 BERKELEY J. INT’L L. 
513, 544–45 (2002). 
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one person depends on another for the money to live, or the treatment that 
could save their life?74 
II. THE PROBLEM: ETHICAL CONCERNS REGARDING CLINICAL 
TRIALS CONDUCTED IN FOREIGN COUNTRIES 
There are multiple ethical concerns, however, regarding clinical trials 
conducted abroad. First, research is often conducted on extremely 
vulnerable populations. Second, trials conducted in foreign countries have 
the potential for significant fraud because of economic disparities and a lack 
of oversight and sanctions for abuse. Last, the citizens participating in these 
trials rarely receive their benefits. 
A. Research Is Conducted on Extremely Vulnerable Populations 
According to a report by the Centre for Research on Multinational 
Corporations (SOMO) approximately 40 percent of trials sponsored by the 
global pharmaceutical industry were conducted in low- and middle-income 
countries in 2005.75 This figure is only increasing with the trend of shifting 
clinical trials overseas to increase profits.76 Furthermore, in industrialized 
nations, less than 50 percent of volunteers complete a clinical trial.77  In 
developing countries, however, 90 percent of trials or more reach 
completion.78 The difference in participation and drug approval between the 
United States and other nations alone is alarming, and raises serious 
suspicions about the methods in which the trials were conducted.  
                                                                                                                  
74 Jacob Schuman, Beyond Nuremberg: A Critique of “Informed Consent” in Third 
World Human Subject Research, 26 J.L. & HEALTH 123, 145 (2012). 
75 Shirley S. Wang et al., Scrutiny Grows of Trials Abroad, WALL ST. J. (Dec. 1, 2008, 
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76 See id. 
77 O’Reilly, supra note 69. 
78 Id. 
For the Love of Drugs 1029 
VOLUME 13 • ISSUE 3 • 2015 
A number of other factors support these concerns. First of all, as 
previously demonstrated, trials done abroad are frequently conducted on 
very vulnerable and desperate populations. Citizens are living in poverty, 
and often lack alternatives. The little money a sponsor uses to incentivize 
participation can completely change a participant’s life. For example, some 
sponsors might pay subjects $400 to participate, which in many developing 
nations is more than a citizen makes in an entire year.79 As George J. 
Annas, head of the Health Department at Boston University’s School of 
Public Health, summarized, 
I’d argue you can’t do studies ethically in a country where there is 
no basic health care . . . [.] You can tell a person there that this is 
research, but they hear they have a chance to get care or else refuse 
their only good chance at care. How can you put them in that 
position and then say they are giving informed consent?80 
Meaningful consent is not only impaired by gross economic disparities, 
but also by illiteracy and cultural differences.81 Many countries present high 
rates of illiteracy (in India, for example, 39 percent of citizens are illiterate) 
and patients are often uneducated.82 Many patients are not informed that 
they are not being treated for a disease, but are instead part of an experiment 
or research study.83 For example, seven babies died in Santiago del Estero, 
Argentina, participating in GlaxoSmithKline’s clinical trial for an 
experimental vaccine.84 The mothers stated they had no idea their children 
                                                                                                                  
79 Schuman, supra note 74, at 135. 
80 Id. at 145–46. 
81 O’Reilly, supra note 69; Eliza Barclay, Sending Medical Research Overseas Troubles 
Scientists, NPR, March 4, 2011 12:55 PM, http://www.npr.org/blogs/health/2011/03/04/ 
134176432/sending-medical-research-overseas-troubles-scientists. 
82 O’Reilly, supra note 69. 
83 Barlett & Steele, supra note 10. 
84 Kelly Hearn, The Rise of Unregulated Drug Trials in South America, THE NATION, 
Oct. 10, 2011, http://www.thenation.com/article/163547/rise-unregulated-drug-trials-
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were enrolled in an experiment.85 In foreign countries, participants are often 
not given proper consent forms, or the information needed to understand the 
ramifications of the trial or their rights as subjects.86 And if they are, the 
information is frequently relayed in a language they do not speak.87 In a 
survey conducted of South African women who participated in an AIDS 
experiment, 99 percent stated they did not believe the hospital would allow 
them to quit once the trial began.88 While it is imperative to consider the 
culture of the country research is completed in, evidence demonstrates that, 
frequently, studies are conducted in ways that are not “optimal for the 
cultural norms of that neighborhood or environment.”89  
B. There Is Incredible Potential for Abuse and Fraud 
While all clinical trials are vulnerable to corruption and fraud, research 
conducted abroad, particularly in developing nations, is especially at risk 
for these abuses. First, there is a severe shortage of trained clinical 
investigators working overseas.90 Second, there are great incentives for 
doctors to not only recommend trials to patients, but also lie about trial 
results. Doctors may get paid multiple times the equivalent of their yearly 
salary for patient recruitment.91 For example, Pharmacia and Upjohn, a 
subsidiary of Pfizer, pays doctors in Latin America approximately $1,300 
per patient for an average study.92 In Budapest, one psychiatrist said US 
drug companies pay him between $1,000 and $2,000 for his work with each 
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Duke Univ.). 
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clinical trial subject that he can recruit. As he asked, “How can I afford not 
to?”93 
Yet, there is no meaningful regulation, oversight, or enforcement to 
prevent abuse. For example, in 2004, the FDA approved Ketek, a drug 
developed by Aventis Pharmaceuticals. Just one month prior to approval, 
one of the company’s researchers, Dr. Anne Kirkman-Campbell, was 
sentenced to 57 months in prison for falsifying at least 91 percent of her 
data.94 She had supposedly enrolled over 400 volunteers, including her 
entire office staff, and approximately 1 percent of the town where she was 
working.95 The $400 she collected per patient could not save her from 
prison.96 However, results from clinical trials conducted abroad, largely in 
Hungary, Morocco, Tunisia, and Turkey, gave the FDA the data it needed 
to approve the drug.97 Within two years, the FDA received 93 reports of 
serious adverse reactions to the drug.98 12 people died.99 
If the FDA ignores falsified data in the United States, what happens with 
data obtained abroad? Francis Weyzig, a researcher at SOMO,100 indicated 
that many locals who are carrying out the work abroad face pressure to 
impress drug company sponsors, who bring them great prestige and money. 
They may be tempted to “cut corners to boost enrollment or reconcile 
                                                                                                                  
93 Id. 






100 SOMO, http://www.somo.nl/?set_language=en (last visited Feb. 14, 2015). SOMO is 
the Centre for Research on Multinational Corporations, an “independent, not-for-profit 
research and network organization working on social, ecological and economic issues 
related to sustainable development.” Id. 
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questionable data[.]”101 As Dr. Marcia Angell, former editor of the New 
England Journal of Medicine, told American Prospect,102 
The essence of research is impartiality. . . . There is no substitute 
for a researcher who is disinterested in the outcome, because it is 
too easy to bias the results either consciously or unconsciously. 
What we are seeing now is the disappearance of impartial 
researchers and institutions . . . . As the economic ties between 
researchers and industry become virtually ubiquitous and manifold, 
you have to worry about the quality of the research.103 
Over 200,000 people in the United States die each year from prescription 
drugs.104 That number certainly has the potential to increase exponentially 
with the growing rate of clinical drug trials abroad. 
The potential for abuse and fraud is also significant because there is a 
lack of sanctions and punishment for those that break the already weak 
regulations. Countries where experimentation is completed rarely punish 
violators, and remedies for relief in the United States are scarce. In the 
1940s, US researchers infected Guatemalan soldiers, prisoners, prostitutes, 
and mentally ill people with potentially lethal sexually transmitted diseases 
(STDs) to test transmission and treatment options.105 1,300 people were 
deliberately exposed to STDs to see if penicillin would prevent infection.106 
Less than half of those infected were treated.107 At least 83 people died.108 
Despite these sobering statistics, the trials were hidden from the public, only 
                                                                                                                  
101 Wang et al., supra note 75. 
102 American Prospect is a bimonthly American political magazine. 
103 Jennifer Washburn, Undue Influence, AM. PROSPECT (Dec. 19, 2001), available at 
http://prospect.org/article/undue-influence. 
104 Barlett & Steele, supra note 10, at 1. 
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uncovered when historian Susan M. Reverby of Wellesley College 
discovered their existence when reading papers from a doctor with the 
federal government’s Public Health Service.109 The only consequences were 
a formal apology from President Barack Obama to Guatemala’s President 
Alvaro Colom on the telephone—in other words, nothing.110  
In Bulgaria, drug researchers conducted experiments without approval.111 
Their punishment consisted of one person receiving a 10-dollar fine from 
the drug testing police force.112 Medical Director Janos Borvendeg of 
Hungary’s National Institute of Pharmacy said that if a serious problem 
were uncovered “we would likely not stop a trial . . . . We would tell them 
how to improve. I don’t like stopping a trial because it costs a company so 
much to put one on.”113 The director general of the country reiterated that 
the agency had no provision to fine or bar researchers.114 
C. There Are Minimal Benefits to Participants Abroad 
With all of the risks presented in clinical trials conducted abroad, are they 
worth it? Who do the trials actually benefit? Very few of the host countries. 
First, educators, researchers, and other bodies participating in research 
abroad argue that the supposed goals of clinical innovation and global 
cooperation are hardly met by clinical trials conducted outside of the United 
                                                                                                                  
109 Ananya Mandal, Guatemalan Syphilis Study in 1940’s Violated Ethical Standards: US 
Presidential Commission Report, NEWS MED. (Aug. 31, 2011 6:09 PM), http://www.ne 
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TIMES (Oct. 1, 2010), http://www.nytimes.com/2010/10/02/health/research/02infect.html 
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States.115 Many have expressed the notion that these trials are simply for 
numbers, not to foster relationships with other institutions, or to recognize 
their contributions as scientists and researchers.116 Professor Mohammed 
Tikly, Head of Rheumatology at the Chris Hani Baragwanath Teaching 
Hospital in Soweto, South Africa, stated, 
A disturbing issue for both [private and public] sectors is the fact 
most trials are designed and finalised before they are brought to us, 
with little if any room for changing the design or 
inclusion/exclusion criteria. . . . Really they are using us for our 
numbers, they are not interested in any intellectual input we make 
in the developing world; it is only about the number of patients we 
can recruit. . . . Let’s be honest, the drug companies are just trying 
to sell their products and believe the experts are all in the Northern 
Hemisphere; we are non-entities.117 
Second, developing nations account for a very small portion of the 
market; the United States, European Economic Community, and Japan 
account for 85 percent of pharmaceutical sales.118 Most pharmaceutical 
testing is done for medicines for the developed world in search of cures for 
ailments like overactive bladders, fibromyalgia,119 arthritis, obesity, heart 
disease, and other degenerative diseases.120 Research is conducted in 
                                                                                                                  
115 WEMOS FOUND., THE CLINICAL TRIAL INDUSTRY IN SOUTH AFRICA: ETHICS, RULES 




117 Id. at 31 (alteration in original). 
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countries where malaria and tuberculosis run rampant, yet a petty 
percentage of research funding is devoted to drugs targeting these diseases, 
the primary ailments of those countries.121 For example, 0.03 percent of 
research and development (R&D) between 1975 and 1992 resulted in drugs 
approved for tropical diseases.122 
Not only are clinically-tested drugs produced for industrialized nations, 
but there are also frequently alternatives to the “new and improved” 
proposed treatments. Most drug research focuses on “follow-ons”—similar 
treatments to drugs already on the market (i.e., different forms of 
antibiotics).123 This makes sense when one considers that pharmaceutical 
companies are constantly attempting to shave costs. If they can produce the 
same pill for less money they will fork over the research costs to do so. In 
fact, pharmaceutical companies only invent approximately half of 
“innovative” drugs.124 Pharmaceutical companies consistently claim that 
pharmaceutical drug prices need to remain high to account for R&D. Yet 
much of this research is publicly funded, and companies spend significantly 
more on advertising and marketing than they do on R&D. Currently, 
companies devote one-third of all sales revenue to advertising and 
marketing their products; this is approximately double what they spend on 
R&D.125 In other words, the majority of pharmaceutical revenue is not spent 
on curing cancer, but on getting constituents to buy the same pill in a 
different color. 
Third, research is often targeted to ensure that companies continue profit 
maximization even after drug approval. In 1998, the Wall Street Journal 




123 Ed Silverman, Who Really Discovers Innovative Drugs?, PHARMALOT (Nov. 16, 
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post market studies.126 Theoretically, post market studies are designed to 
determine the overall risk and benefit balance of the drug in a non-
controlled real life setting.127 Often, however, the trials are “primarily 
designed to secure a company’s market position after a drug has [already] 
been approved.”128 As a former employee of a major drug company noted, 
many of these studies are “designed to support and disseminate a marketing 
message.”129 Instead of efficiency and effectiveness, these studies focus on 
highlighting potential advantages over competitors, promoting awareness of 
“invented diseases,” increasing product name recognition, and encouraging 
other marketing strategies.130 
Even clinical trial testing targeted at tropical diseases or top killers in 
other countries does not provide patients the assurance they will actually 
receive any treatment should they participate in the trial because subjects 
participating in trials abroad are at a greater risk of receiving no treatment 
than are their US counterparts.131 The use of placebo-controlled trials is 
much more popular in other nations, particularly developing and poorer 
nations like Guatemala, Argentina, Slovakia, Estonia, Czech Republic, 
Hungary, Latvia, etc.132 Almost half of the registered studies in those 
countries use placebo-controlled trials, while between one-fifth and one-
third of trials conducted in the United States, United Kingdom, Germany, 
and France use placebo-controlled trials.133 In a placebo-controlled trial, 
some subjects receive a placebo (i.e., no treatment) while others receive the 
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new drug.134 This is in contrast to studies where some patients receive a 
satisfactory treatment known to be effective, and some patients receive the 
new drug.135 While the merits of the use of placebos in clinical trials is hotly 
contested, it is worth noting that companies from the United States use them 
in significantly greater percentages in poorer countries.136 Thus, the most 
desperate populations may not be able to access treatment, even by 
participating in dangerous trials. 
Subjects may also receive “treatment” that scientists know is ineffective 
at treating the disease. For example, in the early 2000s, a US researcher at 
the University of Miami conducted tests on children dying of AIDS in the 
Dominican Republic.137 The National Institute of Health could afford to 
treat the children.138 Instead, however, researchers randomized children into 
two groups—one group received therapeutic massage and the other (control 
group) just met with a nurse for “reading, talking, [and] playing quiet 
games[.]”139 Researchers paid families $120 and left them without any life-
saving drugs.140 As Marcia Angell, senior lecturer at Harvard Medical 
School and former editor of The New England Journal of Medicine, stated, 
“This is a terrible study for a number of reasons, including the fact that it is 
biologically implausible . . . . This would have been impossible to do in the 
US.”141 
Furthermore, even if a subject is fortunate enough to receive treatment 
while participating in the trial, he or she seems certain to lose access once 
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the trial is completed. Even clinical trial testing for the few drugs targeted at 
diseases or illnesses affecting citizens in developing countries are generally 
only available to first world nations once the drug is approved.142 As 
previously mentioned, host citizens often participate in clinical trials 
because it is their only method to access the medication they need to 
survive.143 Yet, their treatment ends soon after the trial is over.144 Thus, 
thousands of participants are left without care while those unwilling to 
participate in the trial in rich countries reap the benefits.145 For example, a 
study in Thailand led to the development of a treatment preventing 
transmission of HIV from infected mothers to their infants.146 However, the 
drug was marketed at a price far beyond what the majority of Thai women 
could afford, rendering the trial virtually useless to the community where 
the trial occurred.147 Numerous trials were conducted in Zambia for 
nitazoxinade (a drug approved to treat parasite diseases), yet the drug was 
never even licensed for use in the country.148 
As FDA Commissioner Margaret Hamburg told Reuter’s Health Summit, 
ensuring proper care for patients is more than just “parachuting in, doing a 
study and leaving without recognition that these patients have really made a 
contribution, taken some risks and deserve to be respected and provided 
with certain broader aspects of care[.]”149 In answering who these clinical 
trials benefit, the only truthful answer can be pharmaceutical companies. 
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III. EXISTING RULES AND REGULATIONS: HOW DOES A CLINICAL 
TRIAL WORK? 
The Federal Drug and Cosmetic Act (FDCA), 21 U.S.C. §§ 301–392 
(among other requirements) sets out guidelines for the drug approval 
process.150 21 U.S.C. § 355 requires that any person wanting to introduce a 
new drug within interstate commerce must first file an application with the 
FDA.151 The FDCA also requires “all new investigational drugs and 
biologics to undergo clinical trials on human subjects to demonstrate the 
safety and efficacy of these products prior to approval for sale in the United 
States.”152 Data to support these applications may be submitted from the 
United States (domestic clinical trials) or other countries (foreign clinical 
trials).153 
The entity initiating the clinical investigation (but not actually conducting 
it) is called the sponsor of the clinical trial.154 Sponsors typically hire 
clinical investigators, who actually conduct the clinical investigation. Some 
companies, like Pfizer and Bristol Myers Squibb, have their own research 
operations in the countries where they conduct clinical trials.155 Many, 
however, rely on additional middlemen—contract research organizations 
(CROs).156 CROs “recruit patients, conduct tests, and analyze data that will 
be submitted to the FDA.”157 They also assist with regulatory compliance 
and marketing and branding.158 CROs may be foreign, and thus are only 
                                                                                                                  
150 See Development and Approval Process (Drugs), U.S. FOOD & DRUG ADMIN. (Oct. 
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regulated and monitored by the foreign governments. In 2010, the CRO 
market was worth $20 billion, “an estimated 100 percent jump” from 
2000.159 
A. Trajectory of a Clinical Trial 
The Investigational New Drug Application (IND) is where FDA 
oversight of a clinical trial begins.160 Sponsors regulated by the FDA who 
conduct research in the United States must first submit an IND. An IND 
sets up the procedure for drug testing and must assure a certain level of 
quality, permit adequate evaluation of the testing, and protect the rights of 
subjects.161 The IND must also contain the results of previous preclinical 
tests and certain information about the drug, including its source and 
manufacture.162 Unless the company or institution hears otherwise, it may 
begin clinical trials 30 days after its application.163 Once an IND has been 
submitted, the FDA may inspect a clinical trial at any point during the trial 
process.164 INDs, however, are not required for clinical trials that are 
conducted exclusively outside of the United States.165 Sponsors may still 
submit data as a part of their marketing applications for trials conducted 
without INDs, as well as in support of current INDs.166 
The first phase of drug testing focuses on clinical pharmacology.167 It 
usually involves a small group of typically 15–30 healthy volunteers and, 
under highly controlled circumstances, is meant to determine “the 
metaboli[c] and pharmacologic actions of the drug in humans, the side 
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161 21 C.F.R. §§ 312, 312.20–312.22, 312.40–312.60 (2015). 
162 Id. at § 312.23; LEVINSON, supra note 11, at 5. 
163 LEVINSON, supra note 11, at 3. 
164 Id. at 4. 
165 Id. at 3. 
166 21 C.F.R. §§ 312.210, 314.106, 321.23 (2015). 
167 21 C.F.R. § 312.21(a) (2015). 
For the Love of Drugs 1041 
VOLUME 13 • ISSUE 3 • 2015 
effects associated with increasing doses, and, if possible, to gain early 
evidence on effectiveness.”168 
The second phase of clinical trials usually involves several hundred 
subjects and focuses on the safety and effectiveness of the drug in treating a 
specific disease.169 Studies are conducted on individuals with the health 
problem the drug is intended to target.170 
The third phase of testing (Phase III) is focused on the widespread 
clinical use to assess effectiveness and dosage.171 It seeks to learn more 
about the benefit risk relationship and involves several hundred to several 
thousand people.172 Phase III studies also provide information to 
disseminate to the general public about the drug, and help determine 
information to put on drug labeling.173 This is where the trial is most likely 
to be outsourced to another country. 
Once Phase III trials are completed, the company or institution must file a 
New Drug Application (NDA) to the FDA’s Center for Drug Evaluation 
and Research (CDER).174 This entails providing reports of the IND 
investigations, information about labels, and samples and statements about 
the drug.175 This step is the principal regulatory device for controlling drugs 
in the United States.176 Once the CDER receives an application, a reviewer 
first ensures that all necessary application materials have been properly 
submitted.177 Afterwards, a series of scientific analyses (i.e., medical, 
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chemistry-based, pharmacology-based, and statistical reviews) are 
conducted on the pivotal trials (as identified by the sponsor) and other 
supporting data.178 Review relies mostly on assurances from sponsors that 
“Good Clinical Practices” (GCP) were followed, and on supporting 
procedural descriptions to ensure compliance with the guidelines.179 If the 
FDA finds that the clinical trials show the new drug is safe and effective, 
the trials were done properly, and all of the data is valid, the FDA may 
approve the drug for marketing in the United States.180 Alternatively, if the 
FDA finds defects in any of the above-mentioned criteria, it may deny 
approval for the drug, after which (if desired) the sponsor may “ask for a 
hearing, correct any deficiencies and submit new information, or withdraw 
the application.”181 
Sponsors may also conduct post marketing clinical trials. As explained 
above, these are studies conducted after the FDA has approved a drug for 
marketing.182 These trials may further confirm or deny the safety of a drug 
after it has been marketed to the greater public.183 They also allow 
companies to study different formulations and dosages of the medication, 
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B. Oversight and Enforcement 
Technically, the FDA has the ability to inspect ongoing clinical trials and 
issues sanctions for inaccurate data and fraudulent conduct. 
1. Inspections 
The FDA begins oversight of clinical trials once a sponsor submits an 
IND Application.185 As previously mentioned, once an IND is submitted, 
the FDA may inspect ongoing trials at any time.186 However, trials may 
occur prior to the submission of an IND, and companies completing trials 
exclusively outside of the United States are not required to submit an IND 
at all.187 
2. Disqualifying Data/Study 
Overall, if a sponsor follows FDA guidelines, the FDA must accept its 
data.188 The FDA has the authority to disqualify data as a result of 
inspection findings and may also disqualify clinical investigators if there is 
evidence of deliberate and repeated noncompliance.189 This remedy is rarely 
taken though, and may take years to complete.190 Additionally, the FDA 
may still accept data that does not conform to its guidelines if it determines 
the data is “reliable and accurate.”191 
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C. Additional Protections for Vulnerable Populations in the United States 
There are also protections built into the Code of Federal Regulations 
(C.F.R.) that safeguard clinical trial subjects against certain risks. First, 21 
C.F.R. §§ 50.20192 and 50.25193 ensures that subjects properly and 
knowingly consent to participating in clinical trials. Section 50.20 provides: 
“[N]o investigator may involve a human being as a subject in research 
covered by the regulations unless the investigator has obtained the legally 
effective informed consent of the subject or the subject’s legally authorized 
representative.”194 “Legally effective informed consent” requires that 
subjects have a sufficient opportunity to consider their participation.195 
Investigators must minimize the possibility of coercion and undue 
influence, and information must be given to subjects in a language spoken 
by them or their representatives.196 Contracts may not include exculpatory 
language through which the subject is required to waive or appear to waive 
any legal rights, or release or appear to release the investigator, sponsor, 
institution, or its agents from liability for negligence.197 There may also be 
additional required safeguards in certain situations to ensure proper 
consent.198 For example, participants must be informed of alternative 
treatment, if available, and must be made aware that they may stop 
participating at any point.199 
Section 50.50(D) also provides for greater protections for children, who 
are considered vulnerable people.200 It lists factors to explain to volunteers 
and mandates that if there is more than minimal risk to the child, then the 
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child subjected to testing must also be a direct beneficiary.201 In other 
words, the drug tested should be intended for child use, and for a disease, 
illness, or ailment that the child tested on actually has. 
Subpart D of 21 C.F.R. § 56202 sets up obligations for Institutional 
Review Boards (IRBs). Prior to an investigation, an IRB must approve the 
setup.203 Additionally, the IRB must monitor and ensure that the 
investigation is conducted in accordance with the approval granted by the 
board.204 Certain disclosures are also required (e.g., the disclosure of 
financial relationships to avoid conflict of interests).205 
D. Protections for Vulnerable Populations in Foreign Countries 
Clinical trials conducted abroad, however, are not held to the same 
regulations, rules, and standards, and there are also no additional safeguards 
to ensure vulnerable populations are protected. Prior to 2008, companies 
conducting clinical trials in other countries were required to follow either 
the Declaration of Helsinki206 or the laws of the host country, whichever 
was stricter or more protective.207 In 2008, however, the FDA adopted 
Guidelines for Good Clinical Practices (GCP).208 These guidelines were 
derived from the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
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and provide the “standard for the design, conduct, performance, monitoring, 
auditing, recording, analysis, and reporting of clinical trials in a way that 
provides assurance that the data and reported results are credible and 
accurate and that the rights, safety, and well-being of trials subjects are 
protected.”209 General principles provided by the document include 
identifying and weighing risks and benefits and using scientifically sound 
design and clear, detailed protocol and qualified investigators and medical 
practitioners.210 Other general principles include accurate and verifiable 
recording and reporting, preservation of confidentiality of subjects, “good 
manufacturing practices,” and freely given consent.211 “Special attention” is 
also required for trials with “vulnerable subjects.”212 The GCP guidelines 
are just that, however—guidelines with discretion on enforcement. 
The FDA claims that GCPs are necessary to give host countries and other 
bodies flexibility.213 It claims that it does not want to place binding 
resolutions on industries outside of its control.214 Additionally, the FDA 
claims that the GCPs are even more protective than the Declaration of 
Helsinki,215 and less confusing to other countries and parties who might not 
know which version of the Declaration is in force.216 However, this paper 
will demonstrate that this standard, whether actually more protective than 
the Declaration of Helsinki or not, still remains inadequate. 
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IV. INADEQUACY OF EXISTING REGULATIONS OF CLINICAL TRIALS 
CONDUCTED ABROAD AND REMEDIES 
While there are a number of regulations in place to protect clinical trial 
subjects abroad, it is clear that existing safeguards are not enough. First, not 
all trials conducted abroad are subject to FDA regulation. Second, the 
regulations themselves are inadequate in that they are not binding and fail to 
incorporate a number of specific necessary protections.  
A. Not All Trials Are Subject to FDA Regulation 
One significant challenge the FDA faces in oversight and enforcement of 
clinical trials is that sponsors conduct many trials, particularly early phase 
clinical trials, outside of the United States without INDs.217 Since FDA 
oversight begins once a sponsor submits an IND, trials conducted before a 
sponsor submits an IND, or trials where a sponsor chooses not to submit an 
IND, proceed without the FDA’s knowledge and, accordingly, without the 
FDA’s oversight and regulation.218 Thus, a significant number of trials 
occur that the FDA has absolutely no knowledge of. The time and money 
required for an IND incentivize sponsors to begin research without them, 
and this trend is not only continuing, but increasing.219 Of course, the FDA 
cannot see the true ramifications of these trials until years after they are 
completed, when the sponsor submits an NDA. 
B. Inadequate Regulations 
Even trials that are subject to FDA regulations lack adequate standards, 
however. The GCPs are not legally binding, and, furthermore, there are 
numerous deficiencies in the GCPs themselves. For example, some claim 
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that the GCPs focus on efficiency over ethics.220 Additionally, the 
guidelines are very general and leave significant room for interpretation.221 
For example, “special protection” and “vulnerable populations” are not 
clearly defined anywhere in the guidelines. This results in multiple 
interpretations of the GCPs and thus, a great variability in how they are 
implemented and how human subjects are protected.222 
The GCPs also fail to provide multiple important and necessary 
protections. First, unlike the ICH, there are no detailed or specific protocols 
for regulating research and obtaining informed consent; in fact there are few 
protections to assure that proper consent is obtained.223 For example, there 
is no language requirement (e.g., that subjects must have access to 
documents in a/the language they speak). Additionally, the requirements to 
show patients gave informed consent are much less vigorous than the 
requirements for trials conducted in the United States.224 The guidelines 
only require that companies not coerce or unduly influence a subject, and 
that the subject should have ample time and opportunity to consider 
participation and have all of their questions answered. Further, requirements 
to meet informed consent standards are only a “condition of acceptance for 
the research.”225 In other words, there are no real penalties for conducting a 
clinical trial without proper consent, other than the rejection of the data, 
which is not an issue for big pharmaceutical companies who are conducting 
numerous clinical trials in multiple countries. Failing to obtain proper 
consent for one country does not mean that the drug is off track for 
approval. 
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Second, there are no specific requirements to provide additional 
protection for vulnerable populations. Unlike researchers bound by US 
requirements, companies conducting clinical trials abroad are not required 
to follow special rules for trials involving children, and there is no direct 
benefit requirement.226 Companies may conduct research for any drug of 
their choosing even if it does not benefit the subject participants or the host 
country.227 They are also free to leave right after the trial without providing 
medication to the participants, follow-up care, or any guarantee that the 
subjects could access the drug if it were to be approved in the future.228 
Third, the GCPs also do not require that drug companies undergo an IRB 
approval process.229 Instead, an Independent Ethics Committee (IEC) must 
“review and approve” a study before it commences.230 Unlike a drug under 
an IRB approval process, an IEC is not required to continually review the 
trials it approves; yearly review is suggested but not mandated.231 
Additionally, like the rest of the GCP guidelines, the definitions for 
responsibilities of the IEC to ensure the rights and safety of subjects are less 
precise. Procedures are not clear or specified, thereby lacking “teeth.” 
A fourth major pitfall of the GCP requirements is that companies and 
institutions are not required to report trials overseas; there is no mandatory 
public record, and thus a lack of real transparency.232 Even the Department 
of Health and Human Services (HHS) inspector general has raised concerns 
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that the “FDA receives minimal information on the performance of foreign 
institutional review boards . . . [and] has an inadequate database on the 
people and entities involved in foreign research.”233 
Another problem arises from the GCP guidelines placing compliance 
burdens on the investigator participating in the trial instead of on the 
sponsor.234 Furthermore, guidelines are mostly limited to implementation 
and maintenance.235 Pharmaceutical companies are only required to provide 
a mostly supervisory role, as they can pass most obligations along to the 
investigators or researchers. Despite their limited responsibilities, 
pharmaceutical companies are largely the beneficiaries of these trials. 
Many pharmaceutical companies argue that standards for all trials 
conducted are fairly universal throughout the globe. However, even if 
regulations were equally powerful and binding worldwide, enforcement of 
these rules is far from universal.236 In fact, there is virtually no oversight of 
clinical trials conducted abroad by sponsors in the United States.237 
C. Challenges in Oversight and Enforcement 
Not only are existing regulations inadequate to adequately protect foreign 
clinical trial subjects, but they are difficult to oversee and enforce. First, 
FDA inspections of abroad sites are difficult to conduct due to logistical 
limitations. Second, the legal burden of following rules and regulations is 
often on the host country, rather than the pharmaceutical company. Third, 
the few inspections that do occur of abroad sites are often conducted far too 
late to address any human rights violations. Fourth, data presented to the 
                                                                                                                  
233 Coyne, supra note 52, at 440. 
234 Finnuala Kelleher, The Pharmaceutical Industry’s Responsibility for Protecting 
Human Subjects of Clinical Trials in Developing Nations, 38 COLUM. J.L. & SOC. 
PROBS. 67, 76 (2004). 
235 Id. at 82. 
236 Gardner, supra note 119. 
237 Cohen, supra note 229. 
For the Love of Drugs 1051 
VOLUME 13 • ISSUE 3 • 2015 
FDA is limited and non-standardized, and easily skirts FDA 
disqualification. 
1. Logistical Obstacles in Inspections Abroad 
While the FDA has the authority to conduct inspections of drug trial sites, 
it is not required to do so and rarely takes advantage of this authority.238 
Despite the increasing numbers of foreign clinical trials, most inspections 
are conducted in the United States. The FDA inspects a mere three to four 
sites per trial, and the majority of those inspections are conducted on US 
sites.239 In 2008, the FDA inspected a mere 1.9 percent of domestic clinical 
trial sites and 0.7 percent of foreign clinical trial cites.240 Further, the FDA 
is “16 times more likely to inspect a clinical investigator at a domestic site 
than a foreign site.”241 One report that reviewed subject enrollment in 
foreign and domestic sites found that Peru, while boasting the fourth largest 
subject enrollment, had not received any FDA inspections.242 Most 
inspections that do occur happen long after a trial is complete.243 
According to FDA officials, inspectors are generally only allowed one 
week to complete inspections, which includes travel time.244 This short 
window barely leaves FDA inspectors enough time to travel to foreign 
countries let alone conduct comprehensive inspections of the site. 
Additionally, the FDA only has 11 inspectors on staff to conduct foreign 
inspections.245 FDA inspectors are generally at the whim of foreign 
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investigators or institutions to conduct tours of the sites and explain the 
research being conducted, and host countries frequently supply the 
translators for inspections done in other countries.246 Given these 
limitations, and the fact that inspections generally occur once a test has 
concluded, FDA inspections usually focus on paperwork: “Were the right 
forms filed? The right diagnostic tools used? Medical records kept 
accurately?”247 
2. Oversight and Enforcement at the Burden of the Host Country 
As such, the real oversight and enforcement for trials is in the hands of 
the host country, which puts the burden of time and money on the 
investigator. Yet, many countries lack their own oversight and the proper 
resources and regulatory structure to ensure GCP standards are met.248 
Many of the foreign sites are already understaffed and frequently do not 
have enough investigators and/or coordinators to conduct proper research, 
let alone give tours of the site and explain the ongoing trials.249 In fact, 
some foreign study-coordinators are responsible for supervising as many as 
30 different sites.250 Additionally, many physicians, researchers, and other 
staff lack experience conducting clinical trials of the type US sponsors seek 
to conduct.251 Foreign officials are not prepared for this burden shift, and 
the shift is not fair. 
On the other hand, there are tremendous financial and economic 
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and doctors, to have clinical trials that result in drug approval. There is a 
lucrative market for drug applications and, as shown above, a lot of profit to 
be made in the pharmaceutical industry from new medication. In many 
unindustrialized countries, there is a severe lack of functioning health care 
systems, but enormous financial incentives for investigators and doctors to 
participate in the clinical trial. Foreign IECs and IRBs are also frequently 
less experienced and have similar financial incentives should the trial 
succeed. Many for-profit companies have popped up “to sell their ethical 
review services to the highest bidder.”252 There is no real threat of audits or 
oversight, so workers on site can give an incredibly incomplete picture of 
what is actually occurring in the trial, and foreign trials have the potential to 
yield high “positive” results. Thus, there is no assurance that the FDA has 
any real picture of what is actually occurring in FDA-regulated trials. 
3. Inspections Late in the Game 
The high cost of visas, translators, and transportation certainly makes 
foreign inspections less appealing than those in the United States. This is 
probably why the review that rarely does occur, happens very late in the 
game.253 Of the few inspections the FDA makes, most occur after the FDA 
receives a marketing application from a sponsor, as opposed to when a 
clinical trial is ongoing, and most are focused on verifying the accuracy of 
the data.254 For example, a South African center violated FDA regulations, 
but citations were not issued until two years after the violations occurred.255 
In Romania, a researcher died three years before the center even received a 
citation.256 In an interview conducted by Chris Hansen of Dateline NBC, 
former FDA Commissioner Dr. David Kessler expressed fear about the 
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risks regarding clinical trials and the FDA’s ability to regulate and monitor 
these trials:  
“‘What’s going to happen, and I can predict this . . . it’s been the history 
over the last 100 years. We don’t act until there’s a problem.’  
‘Until people die?’ Hansen asked.  
‘Regrettably.’”257  
In fact, David A. Lepay, the FDA’s director of investigations, estimated 
that over 90 percent of clinical trials done overseas are not reported in 
advance to the FDA.258 This just further reiterated that the FDA has no 
knowledge of what is going on in these trials abroad. 
4. Non-Standardized Data 
Additionally, there is no fixed standard format for data submission. Data 
is often presented inconsistently, “making it difficult to locate [needed] 
clinical trial information,” and sponsors frequently fail to provide important 
information in their reports, including site location and subject 
enrollment.259 Additionally, sponsors usually submit clinical study reports 
in “portable document formats” (PDFs), which the FDA may not analyze 
directly.260 In a report completed by the Office of the Inspector General, the 
FDA could not provide detailed clinical trial data for over 20 percent of the 
applications the agency sought to review.261 And, the FDA was unable to 
locate any portion of virtually one-third of those incomplete applications.262 
Of the final applications found, some applications were in paper form and 
some were in electronic form, and in many of them sponsors failed to 
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include site locations and subject enrollment.263 This practice would have 
been completely unacceptable in the United States, yet neither the FDA nor 
the pharmaceutical companies at fault have presented a remedy to account 
for this completely missing information. 
D. Potential Avenues for Relief Fall Short 
Currently, means for enforcement are limited and avenues of relief for 
individuals wronged by clinical trials are few and far between. To begin, 
FDA remedies offer little more than a slap on the wrist to companies who 
violate regulations or laws. Additionally, there are few methods for 
individuals harmed to bring suit against foreign pharmaceutical companies.  
1. FDA Remedies 
The FDA has the authority to enforce an IND through injunctions and 
criminal prosecutions; however, this action is rarely taken.264 To make 
matters worse, should a sponsor or investigator violate GCP guidelines, 
there are no penalties other than rejection of their data, which the FDA will 
still examine even though it will not accept it.265 In other words, the FDA 
would not do anything to punish unethical researchers; it would only 
disqualify their data.266 Additionally, even if a sponsor’s conduct injures or 
kills a subject, FDA regulations do not require that the sponsor “administer 
post-trial care, compensate participants, or in the event of death, 
compensate the participant’s family.”267 
                                                                                                                  
263 Id. 
264 21 U.S.C. §§ 331(e)–333 (2012). 
265 Schuman, supra note 74, at 135. 
266 Wilson, supra note 60, at 660. 
267 Stacey B. Lee, Informed Consent: Enforcing Pharmaceutical Companies’ Obligations 
Abroad, 12 HEALTH & HUM. RTS. J. 15, 23 (2010), available at http://www.hhrjournal. 
org/wp-content/uploads/sites/13/2013/07/4-Lee.pdf. 
1056 SEATTLE JOURNAL FOR SOCIAL JUSTICE 
SEATTLE JOURNAL FOR SOCIAL JUSTICE 
2. International Covenant on Civil and Political Rights (ICCPR) 
In 1966, the United Nations (UN) incorporated the concept of informed 
consent into the ICCPR as a human right. Article 7 states that “no one shall 
be subjected without his free consent to medical or scientific 
experimentation.”268 However, the ICCPR, while conferring absolute rights, 
is not self-executing. It has not yet been applied in a human rights lawsuit 
against a state actor and does not create a binding legal obligation 
enforceable in federal court. Thus, clinical trial subjects abroad cannot use 
the ICCPR as a legal document to file suit against pharmaceutical 
companies in the United States.269 
3. Alien Tort Statute 
The Alien Tort Statute (ATS) (28 U.S.C. § 1350) states “the district 
courts shall have original jurisdiction of any civil action by an alien for a 
tort only, committed in violation of the law of nations or a treaty of the 
United States.”270 Action under the ATS, however, is very limited. The only 
ATS case the US Supreme Court has ruled on is Sosa v. Alvarez Machain. 
In Sosa, the court held that the ATS was “intended only to prohibit conduct 
for a moderate number of new international law violations that were 
sufficiently ‘specific, universal and obligatory.’”271 
Following the Trovan experiments, discussed at the beginning of this 
paper, families of the dead and injured children realized they had few 
avenues for relief aside from the ATS. They filed suit against the 
pharmaceutical company Pfizer under the ATS for violating “a norm of 
customary international law prohibiting medical experimentation on non-
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consenting human subjects.”272 Their claim was initially dismissed by the 
district court, but on appeal, the Second Circuit reversed. The appellate 
court explained that, in considering whether an international norm is 
sufficient to bring a cause of action under the ATS, the court must examine 
whether the norm is accepted by the international community and whether 
states universally abide by the norm out of a “sense of mutual concern.”273 
Additionally a court must examine current norms compared with eighteenth 
century paradigms in place when the ATS was first enacted.274 The court 
found that nonconsensual drug trials, thus, violated customary international 
law.275 Pfizer subsequently filed a writ of certiorari, but the Supreme Court 
denied the writ, thereby declining to hear the case.276 
While the Pfizer case may bring hope to those injured by improperly 
conducted clinical trials, it is difficult to say how far, if anywhere, the 
holding may actually reach. Sosa v. Alvarez-Machain277 seems to leave very 
little of the statute for potential plaintiffs to work with.278 Thus, while a 
lawsuit was successful for one plaintiff, there is no indication that it would 
be successful again. Because the Supreme Court has yet to interpret whether 
the ATS applies to pharmaceutical companies conducting trials abroad, it is 
very difficult to predict how a court might rule on a case similar to Pfizer.  
4. Foreign Corrupt Practices Act 
The Foreign Corrupt Practices Act (FCPA) makes it illegal to offer or 
make corrupt payments to foreign officials for the purpose of securing or 
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retaining business.279 Critics of pharmaceutical company activities in 
developing nations have more recently relied on the use of this statute to 
punish human rights violators. In 2009, Assistant Attorney General Lanny 
Breuer warned, the Department of Justice will be “intensely focused on 
rooting out foreign bribery in [the pharmaceutical] industry[.]”280 
Additionally, the law is defined now such that any government employee 
may be considered a foreign official; generally anyone working for a public 
healthcare system may be subject to the Act.281 
Thus, the FCPA is certainly a meaningful avenue for relief. However, it 
is limited to punishing employees who make or receive corrupt payments. 
While pharmaceutical companies and sponsors may be held accountable for 
corrupt exchange of money, there are no protections for individuals who 
were not properly informed of the risks of the trial or did not give adequate 
consent.282 Additionally, of course, the Act fails to solve the underlying 
issue. It is not until after a subject is severely injured or dies that the lawsuit 
will take place. Litigation is definitely a powerful avenue for relief, but it is 
usually the least preferable method when discussing human rights abuses. 
5. Foreign Lawsuits 
Although host countries may be able to file suit against drug trial 
sponsors, injured citizens are not assured any direct benefit from such 
lawsuits. Developing nations may not even have the resources to bring suit 
in the first place. The outcome of any such suit also has serious underlying 
ethical problems. For example, the government of Nigeria sued Pfizer in 
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Nigerian Federal High Court claiming the company never “obtained 
approval of the relevant regulatory agencies . . . nor did the defendant seek 
or receive approval to conduct any clinical trial at any time before their 
illegal conduct[.]”283 In 2009, Pfizer settled with its 200 plaintiffs out of 
court for $75 million.284 This case raised serious ethical concerns. First, 
according to a leaked US embassy cable, Pfizer hired investigators to 
unearth evidence of corruption against the Nigerian attorney general to 
persuade him to drop charges against the company.285 Second, interestingly, 
a few months after the settlement, the medical records of the victims could 
“not be found” at either the Kano State Ministry of Health or at the 
Infectious Diseases Hospital where the clinical trials were conducted.286 
V. MEANINGFUL SOLUTIONS 
Neglecting foreign nations is far too easy, despite the strong presence of 
US companies in those countries. US companies should have the same 
standards for treatment, regardless of where a human subject resides; 
citizens of other countries deserve the same protections that citizens of this 
country are guaranteed. 
In case international human rights are not enough of an incentive to 
induce action, let us not forget the significant number of pharmaceutical 
drugs that have already been approved for market in the United States 
primarily, or entirely, as a result of clinical trials conducted in other 
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countries. Experiments conducted under current regulations not only have 
severely harmed citizens abroad, but also have had dire consequences for 
citizens in our own country. For example, not only did the Trovan 
experiment lead to a number of deaths and disabling conditions for Nigerian 
children, but within the first 16 months of its approval, there were also 140 
reports of liver problems, at least 14 reports of liver failure, and six deaths 
in the United States.287 Clinical trials present an incredible method to 
facilitate drug innovation and lifesaving cures. However, the current 
beneficiaries of these trials are mostly pharmaceutical companies. The risk 
of these experiments should instead be just as great for drug sponsors as it is 
for drug trial participants, if not greater. A number of mechanisms could 
reduce the number of, and potential for, unethical and dangerous clinical 
trials. 
A. Binding Regulations 
There are a number of regulations that should be enacted to adequately 
protect the human rights of individual subjects in US clinical trials 
conducted abroad. To begin, the standards for trials conducted abroad 
should be just as stringent and protective as those conducted in the United 
States. Additionally, all trials conducted should be published in a public 
registry and database, and data should be standardized. Inspections should 
be targeted and more frequent, and regulatory US agencies should develop 
stronger and closer relationships with host countries. Lastly, subjects tested 
on should receive some form of benefit from the trial and its results. 
1. US Standards 
First, at the very minimum, pharmaceutical companies conducting 
research in foreign countries ought to be subject to the same minimum 
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standards as if they were conducting the trials in the United States. This 
would require companies to submit an IND and secure approval from an 
IRB. Additionally, companies would be held to the same requirements of 21 
C.F.R. § 50, which provides specific requirements for obtaining consent, 
and additional safeguards for children in clinical investigations. 288 
All sponsors should be subject to FDA regulation to ensure proper 
oversight and remedies. An IND requirement first ensures that the FDA is 
aware of all trials currently being conducted. Second, it would require that 
clinical trials be approved by an IRB.289 IRBs have more stringent approval 
and oversight requirements than IECs. The standards IRBs must meet are 
also more clear and comprehensive. Third, the IND requirement would 
ensure that sponsors are held to the same informed consent standards. For 
example, sponsors would be required to provide information in the 
participants’ language of choice and disclose their methods of obtaining 
consent. Informed consent is especially vital with vulnerable populations. 
Subjects must understand the nature of the experiment they are participating 
in, the risks and potential benefits of the experiment, and the reality of 
aftercare treatment once the experiment is over. No company should ever be 
allowed to conduct an experiment without explaining its ramifications to a 
subject in a language they speak. Such a violation would be unimaginable in 
the United States and this conduct should not be permitted by US 
companies regardless of where the conduct occurs. Finally, this requirement 
would allow the FDA to enforce the approved IND through injunctions 
and/or criminal prosecutions (versus simply rejecting data).290 This would 
deter at least some fraud and abuse in the clinical trial because 
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consequences for violating the rules and regulations are more than just a 
slap on the wrist. 
2. Mandatory Public Registry 
The FDA should also require registration for all clinical trials, regardless 
of the success of the trial and country in which the trial takes place. Trials 
that were not reported should no longer be accepted in the approval process 
for drugs. Prior to 2007, reporting was voluntary unless the trial was 
conducted (1) to test the effectiveness of experimental treatments for (2) 
“serious or life-threatening diseases or conditions” (3) under the “FDA’s 
Investigational New Drug (IND) regulations.”291 This regulation limited 
reporting requirements in three major ways—exempting most trials 
conducted abroad from this reporting requirement.292 In 2007, Congress 
expanded the scope of applicable clinical trials and informational 
requirements for mandatory FDA reporting by enacting the Food and Drug 
Administration Amendments Act (FDAAA).293 However, numerous 
questions remain as to how the FDAAA applies to foreign trials.294 Without 
mandatory reporting, companies are incentivized to self-select which 
clinical trials (i.e., the successful ones) to report, resulting in incomplete and 
biased views of the results.295 Also, without mandatory reporting, if a 
company holds unethical or dangerous trials that are unsuccessful, the 
company may just choose to not submit those trials as part of an IND or 
drug marketing application. A public registry requirement for all trials 
                                                                                                                  
291 Carolyn R. Hathaway et al., The Web of Clinical Trial Registration Obligations: Have 
Foreign Clinical Trials Been Caught?, 64 FOOD & DRUG L.J. 261, 262 (2009) (emphasis 
in original). 
292 Id. 
293 Id. at 263–66. 
294 Id. at 269. 
295 WORLD HEALTH ORG. (WHO), INTERNATIONAL CLINICAL TRIALS REGISTRY 
PLATFORM (ICTRP), REPORTING OF FINDINGS OF CLINICAL TRIALS (2011), available at 
http://www.who.int/ictrp/results/en/. 
For the Love of Drugs 1063 
VOLUME 13 • ISSUE 3 • 2015 
would ideally provide for more objective and comprehensive data 
collecting. It would hold companies more accountable in ensuring their 
clinical trials were conducted ethically, both to the public and to oversight 
organizations. A public registry would allow the public and media to more 
easily examine these trials, demanding change and using the market as a 
strategy for punishment when necessary and as a deterrent. The registry 
would also give oversight committees more information for approval. In 
analyzing whether a drug should be approved or not, the FDA would have 
all of the necessary data to make a truly informed decision. It would have 
access to more than just the trials a drug company deems relevant. 
3. Standardized Electronic Trial Data and an Internal Database (for 
the FDA) 
The mandatory reports should be standardized and in electronic form to 
ensure that any potential viewers always have the most current data 
available to effectively analyze them. This would help the FDA conduct 
trend analysis, identify sites and sponsors that pose the most risks, and form 
a comprehensive database of trial sites where there are adverse events or 
that have histories of noncompliance.296 Pharmaceutical companies might 
argue that additional oversight will cost more time and money to the agency 
or regulatory bodies, but standardized data would allow for better, quicker, 
and more efficient review. This method helps to ensure that the drug 
sponsor will be the entity to incur any additional costs. This would also 
prevent situations like that in Kano, where all records of the individuals 
participating in the trial magically “disappeared.” 
4. More Efficient Inspections 
The FDA is currently developing a computer-based program referred to 
as a “site selection tool” in order to maximize resources in clinical trials. 
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This would allow the FDA to select sites for inspection based on specific 
risk factors.297 The FDA should continue development of this software, as 
well as look at other methods of oversight to determine which trials pose the 
most risks to host country subjects. This would not prevent companies from 
conducting necessary trials in the most risk-prevalent countries, but rather 
would increase oversight of these trials to ensure the subjects remain 
protected. 
5. Foster Relationships with Host Countries 
Additionally, the FDA should work more closely to foster relationships 
with foreign regulatory bodies and governments. If officials worked 
together to create an international registry or database to share results of 
inspections and keep each other up to date, the FDA could better maximize 
its resources, as well as give governments additional incentive to protect 
their individual citizens. Getting all governmental bodies on the same page 
would also send the message that compliance with these regulations is 
important and enforcement is a real threat. 
6. Increase Inspection Frequency and Funding 
The FDA should also inspect more clinical trials in more countries. It 
should pay specific attention to trials conducted by companies who have 
falsified data or violated standards in the past, as well as countries 
especially vulnerable and/or susceptible to corruption or abuse in research. 
This mechanism may be costly and resource consuming. Thus, 
pharmaceutical companies should be required to pay for onsite inspections 
conducted by the FDA, similar to the Prescription Drug User Fee Act 
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(PDUFA).298 PDUFA authorizes the FDA to collect fees from drug 
manufacturers to support the drug approval process.299 The FDA could 
increase these fees—which currently account for roughly one-quarter of the 
agency’s spending—to allow for better enforcement and to ensure the 
burden, again, is on the drug sponsor.300 The FDA could also reconsider the 
current allocation of funds collected and re-examine the most effective and 
efficient method to use the fees being generated to ensure ethical, safe, and 
accurate clinical trials. 
7. Benefits Requirement 
Additionally, companies conducting research abroad should have new 
required benefits. Currently, if sponsors complete testing on children in the 
United States, they must go through three levels of approval. Clinical trials 
may proceed, first, if the IRB finds that there is no greater than minimal risk 
to the children. If there is greater than minimal risk, the risk must be 
justified by the anticipated benefit to the subjects. Investigators must show 
that the “relation of the anticipated benefit . . . is at least as favorable to the 
subjects as that presented by available alternative approaches; and . . . 
[a]dequate provisions are made for soliciting the assent of the children and 
permission of their parents or guardians[.]”301 Additionally, investigators 
generally must show that the same research could not be carried out on less 
vulnerable subjects and that subjects will be “assured reasonable access to 
any diagnostic, preventative or therapeutic products that become available 
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as a consequence of the research.”302 There are also very strict requirements 
for obtaining consent by parents and guardians.303 
There are some exceptions to these general requirements (for example, if 
the procedure or intervention will likely yield generalizable knowledge 
about the subjects’ disorder that is of vital importance to understanding it), 
but these exceptions are still severely limited and still require some sort of 
benefit to the subject.304 These requirements should extend to any 
participant in another country. In other words, companies would be required 
to show that the host country would benefit directly from the drug trial 
conducted any time the trial poses more than a minimal risk. There is a 
similar benefit assurance guideline in the International Ethical Guidelines 
for Biomedical Research involving Human Subjects.305 Additionally, post-
trial treatment, if effective, should be provided to the subjects of the clinical 
trial upon drug approval (should the subjects desire it). While a drug 
company cannot ensure that a foreign country will approve marketing or 
sell the pharmaceutical, there should at the very least be follow-up care 
provided for drug trial subjects. 
B. Stricter Enforcement and Sanctions 
As previously mentioned, all sponsors should be required to submit an 
IND and be under FDA supervision. Sponsors should be held accountable 
for any violations instead of simply having their data disqualified. In 
addition, governments should also work together to create an international  
tribunal that has the authority to police trials, similar to the UN or World 
Health Organization. For drug companies to participate in clinical trials in 
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those countries, participating in the tribunal for resolving disputes would be 
mandatory. This would further enforce the message that institutions are to 
follow certain standards when conducting clinical trials and assure 
companies that there are sincere threats of oversight and consequences for 
violations. Additionally, countries could draw on trade-related aspects of 
international property rights. For example, they could deny intellectual 
property protections to drug companies who have developed drugs through 
trials that violated rights of participants. This would also alleviate 
pharmaceutical company concerns that the United States is being 
paternalistic. A tribunal would give countries an opportunity to work 
together to achieve common goals. 
CONCLUSION 
Clinical trials are a critical part of drug development. They are an integral 
step in defeating illness, preventing pandemics, and finding cures to 
diseases, chronic illnesses, and detrimental conditions. However, the 
potential benefits of clinical research must not be completely offset by the 
costs. Subjects of clinical trials conducted abroad are especially susceptible 
to exploitation and it is imperative that clinical trial sponsors, not the 
participants or regulators, feel the brunt of these burdens. Human lives 
should never be sacrificed for money. 
  History has demonstrated the importance of proper regulation of clinical 
trials. While research may save lives, it should not be at the cost of others’ 
lives. It is vital that subjects risking their entire future understand the full 
risks of their participation, and that they have the assurance that they can 
trust the process. Properly conducted trials are essential for participants, as 
well as future users of the medication. How many more lives are we willing 
to lose to pharmaceutical profits? 
